三生国健：613项目急性痛风性关节炎适应症已于2025年6月份向国家药品监督管理局提交上市申请并获得受理

Group 1 - The core viewpoint of the article is that Sanofi's 613 project for acute gouty arthritis has submitted its application for market approval to the National Medical Products Administration, which has been accepted [2] - If the product is approved, the company will comply with the relevant regulations of the Shanghai Stock Exchange's Sci-Tech Innovation Board and will issue timely announcements [2]